Will TRXC Survive?

Will TRXC survive? TransEnterix (NYSEAMERICAN:TRXC) now has plenty of cash to survive well into 2024, which will allow the laparoscopy robotics company to eventually produce revenue.

Why did TRXC stock drop so much?

On April 12, Tian Ruixiang Holdings (TIRX) stock fell 79.5 percent and closed at $18. The stock fell despite no company-specific news or an analyst downgrade. So, what caused TIRX stock to fall significantly? It seems to be the social media-driven pump-and-dump scheme that's driving wild fluctuations.

What is TRXC company?

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will change its corporate name to Asensus Surgical, Inc.

What happens to TRXC stock?

Also today, TRXC had its Investor Day presentation, where it announced it would be changing the company name to Asensus Surgical. TRXC stock will begin trading under the new name and ticker ASXC on March 5, 2021.

Is TransEnterix a buy?

TransEnterix currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. While any stock can see its price increase, it takes a real winner to consistently beat the market.


Related investments for Will TRXC Survive?


Does TransEnterix have a future?

TransEnterix has projected its cash runway to last until the end of 2022. There are also many regulatory catalysts anticipated in the first half of 2020 that can further push up share prices. TransEnterix is expecting the FDA's clearance for use of the Senhance system in general surgery indication.


Who owns ascensus Surgical?

Ascensus

Type Private
Industry Financial Services
Founded 1980
Headquarters Dresher, Pennsylvania , United States
Key people David Musto (President & CEO) Bob Guillocheau (Chairman)

Why did TransEnterix change its name?

TransEnterix has changed its corporate name to Asensus Surgical, reflecting the firm's vision to shape surgery's future by integrating computer vision and machine learning with surgical robotics.


Who owns TRXC stock?

Top 10 Owners of Asensus Surgical Inc

Stockholder Stake Shares bought / sold
BlackRock Fund Advisors 6.15% +47,894
SSgA Funds Management, Inc. 5.06% +5,314,784
The Vanguard Group, Inc. 4.60% -288,977
Geode Capital Management LLC 1.66% +114,499

Why is TRXC stock up?

TransEnterix (NYSEAMERICAN:TRXC) is seeing shares of TRXC stock soar higher on Tuesday following an update concerning its Intelligent Surgical Unit (ISU). A TransEnterix news release reveals that the company's ISU has been granted CE Mark approval. That opens the device up to be sold in Europe.


What is TRXC trading at today?

TRXC Price/Volume Stats

Current price $4.08 52-week high
Day low $3.62 Volume
Day high $4.77 Avg. volume
50-day MA $3.04 Dividend yield
200-day MA $1.09 Market Cap

Is TransEnterix overvalued?

Instead, TransEnterix will probably try to sell equity, like it did in September 2019. As a result, the risk of dilution on this name is very significant. With regards to the valuation of the shares, we believe that TransEnterix is quite overvalued at 14x forward sales.


Is TRXC a sell?

In short, this is how much a company is worth.

Momentum Scorecard. More Info.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.42%
2 Buy 19.05%
3 Hold 10.68%
4 Sell 6.41%

Is TRXC a stock?

Yes, TRXC stock is tied to a groundbreaking innovation so it's going to get a rich premium, but there's also a limit to what people will pay, especially at these lofty levels.


Will TRXC get FDA approval?

TransEnterix (NYSE:TRXC) said today that it has received FDA 510(k) clearance to add an artificial intelligence feature to its Senhance robotic surgery system.


Is TRXC FDA approved?

Asensus Surgical announces FDA clearance for Senhance Surgical System. Asensus Surgical, formerly TransEnterix, Inc. (NYSEMKT:TRXC) has announced that the company received an additional FDA clearance for the Senhance Surgical System sending TransEnterix shares ~28.1% higher in the pre-market.


Did TRXC change its name?

Asensus Surgical (NYSE:ASXC) announced today that it formally completed its name and stock ticker change from TransEnterix (NYSE:TRXC). Research Park Triangle, N.C.-based Asensus announced last month that the company would change its name from TransEnterix to Asensus Surgical and introduce a new surgery category.


Is ascensus publicly traded?

Ascensus is not yet publicly traded, so there are no official records providing details about the company's market cap. However, you can make some estimates based on recent transactions like acquisitions, divestments, mergers, etc.


Is ascensus a good company?

Great Place to Work, Great management, retirement plan, Benefits. Ascensus gives you the oppertunity to work and show your talents. The salary is competitive and the work life balance is good.


Is ascensus part of Vanguard?

Optional services to be provided by third-party providers that are not affiliated with Vanguard. Investments are subject to risk. Investments in bond funds are subject to interest rate, credit, and inflation risk. Ascensus is not affiliated with VMC, The Vanguard Group, Inc., or any of its affiliates.


What is a lap procedure?

Laparoscopy is a type of surgical procedure that allows a surgeon to access the inside of the abdomen (tummy) and pelvis without having to make large incisions in the skin. This procedure is also known as keyhole surgery or minimally invasive surgery.


Who owns ASXC?

Common Stock (ASXC) Institutional Holdings | Nasdaq.

New and Sold Out Positions.

OWNER NAME FIRST TRUST ADVISORS LP
SHARES HELD 2,524,184
CHANGE (SHARES) 468,367
CHANGE (%) 22.783%
VALUE (IN 1,000S) $3,307

Is check stock a buy?

Check-Cap has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.


Was this post helpful?

Leave a Reply

Your email address will not be published.